Growth Investing Risks

Business

Chemed's Stock Slump Sparks Valuation Debate: Undervalued Opportunity or Warning Sign?

Chemed Corporation (NYSE: CHE) has seen its share price soften recently, reigniting investor debate over whether the healthcare services provider is now undervalued. With the stock trading around $430, a significant gap exists against some fair value estimates, even as operational challenges in its VITAS and Roto-Rooter segments loom.

Jan 30, 2026

Business

Analysts Revise Target for Invesco Mortgage Capital, Signaling Shift in Market Sentiment

A revised price target for Invesco Mortgage Capital (IVR) is prompting investors to reassess the mortgage REIT's trajectory amid evolving interest rate expectations and housing market dynamics.

Jan 30, 2026

Business

Comcast's Stock Slump: A Buying Opportunity or a Sign of Deeper Trouble?

As Comcast shares languish near multi-year lows, a stark divide emerges between its market price and fundamental valuations. We examine whether the telecom and media giant's cash flow potential justifies a contrarian bet.

Jan 30, 2026

World

Exclusive: Europe's $500 Billion Crisis Fund Eyed for Defense Loans Amid Rising Geopolitical Tensions

The head of the European Stability Mechanism has told Reuters the bloc's 430-billion-euro emergency fund could be repurposed to provide defense loans to member states, signaling a strategic shift as Europe seeks to bolster its military autonomy.

Jan 30, 2026

Business

Trump Taps Former Fed Governor Kevin Warsh for Top Central Bank Role, Signaling Policy Shift

President Donald Trump's nomination of Kevin Warsh to lead the Federal Reserve sets the stage for a potential pivot in U.S. monetary policy, placing a seasoned yet controversial figure with deep Wall Street ties at the helm.

Jan 30, 2026

Business

Truist Stands By DLocal With Price Target Hike, Eyes Strong Q4 Amid Tough Comparisons

Analysts at Truist reaffirm their Buy rating on DLocal (DLO), raising their price target to $17 ahead of the fintech firm's Q4 2025 earnings. While expecting solid results, they flag challenging year-over-year volume comparisons that may cap upside surprises.

Jan 30, 2026

Business

Goldman Sachs Lifts Zeta Global Target to $26, Eyes Software M&A Wave on Horizon

Goldman Sachs raises its price target for Zeta Global (ZETA), citing strategic positioning ahead of an expected surge in software sector mergers and acquisitions driven by valuation gaps and synergy potential.

Jan 30, 2026

Business

Alumis Soars as Psoriasis Drug Hits All Phase 3 Goals, Drawing Bullish Analyst Praise

Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.

Jan 30, 2026

Business

BTIG Upgrades Annaly Capital to 'Buy', Citing Dividend Appeal in Volatile Rate Environment

Analysts at BTIG have upgraded mortgage REIT Annaly Capital Management (NLY) from 'Neutral' to 'Buy', with a $25 price target, arguing the stock is positioned to benefit from dividend stability and potential spread movements in a turbulent interest rate landscape.

Jan 30, 2026

Business

Piper Sandler Stays Bullish on AGNC Investment, Sees Opportunity in Narrowing MBS Spreads

Analyst firm Piper Sandler reiterates its Overweight rating on AGNC Investment Corp., highlighting a favorable shift in agency mortgage-backed securities spreads that could bolster the REIT's book value.

Jan 30, 2026

Business

Wall Street Bets on SharpLink Gaming: Analysts See Upside Despite Crypto Volatility

SharpLink Gaming (NASDAQ: SBET) is drawing bullish attention from major Wall Street firms, with multiple analysts reiterating Buy ratings. The company's substantial Ethereum holdings and management's crypto expertise are seen as key drivers, even as price targets adjust to market conditions.

Jan 30, 2026

Business

LifeSci Capital Boosts Price Target on Olema Pharmaceuticals, Citing Promising Breast Cancer Drug Pipeline

LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.

Jan 30, 2026

Business

Progress Software Surges on Strong Earnings, Analyst Upgrades

Progress Software Corporation (PRGS) sees bullish sentiment from Wall Street following its Q4 2025 results, with analysts highlighting its growing recurring revenue and strategic positioning in the enterprise software market.

Jan 30, 2026

Business

Immunocore Gains Analyst Backing as Late-Stage Trials Loom

Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.

Jan 30, 2026

World

Trial Begins for Italian Officials Over Deadly 2023 Migrant Shipwreck

Six Italian police and coastguard members face trial for alleged negligence in the Cutro shipwreck that killed at least 94 migrants, a case testing Italy's hardline migration policies.

Jan 30, 2026

Business

Truist Trims Tesla Target to $438, Maintains Hold as AI Pivot Weighs on Margins

Truist Securities has slightly lowered its price target on Tesla shares to $438, citing the significant capital expenditure required for the automaker's aggressive shift towards AI and robotics, despite a solid Q4 performance.

Jan 30, 2026

Business

Tesla Gets a Boost: TD Cowen Raises Price Target to $519, Citing Mixed Q4 Signals

Investment firm TD Cowen has increased its price target on Tesla (TSLA) to $519, maintaining a Buy rating. The adjustment follows a fourth-quarter performance marked by strong margins and progress on autonomous driving projects, though tempered by higher capital expenditure forecasts and vague timelines for full self-driving technology.

Jan 30, 2026

Business

Truist Trims Landstar System Price Target to $145 Amid Earnings Disappointment

Truist Securities has lowered its price target on Landstar System (LSTR) from $150 to $145, maintaining a Hold rating following the logistics provider's fourth-quarter earnings miss. Analysts cite one-time insurance costs as a drag, while noting core fundamentals have yet to show a decisive turnaround.

Jan 30, 2026

Business

Truist Lifts Meta Price Target to $900, Citing AI-Driven Ad Strength and Upbeat Guidance

Truist Securities raises its price target on Meta Platforms to $900, maintaining a Buy rating. The upgrade follows stronger-than-expected Q4 results and a robust Q1 outlook, driven by AI enhancements boosting ad performance and user engagement.

Jan 30, 2026

Business

C.H. Robinson Gets Price Target Boost to $194 as TD Cowen Cites Resilient Q4 Performance

Analysts at TD Cowen have increased their price target on logistics giant C.H. Robinson to $194, citing better-than-expected fourth-quarter results and margin resilience in a tough spot market, while maintaining a Hold rating.

Jan 30, 2026